Lytix Biopharma AS provided an update at the recent BIO conference in Chicago Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.

During a session hosted by the European Cancer Cluster (Norwegian Oslo Cancer Cluster and French Cancer-Bio-Santé Cluster) at the recent BIO conference in Chicago, Head of Lytix Biopharma Business Development Anders Fugelli, PhD provided an update on the Phase I study of Oncopore™ (LTX-315) for the treatment of solid tumours.  The study is set up to include patients at two main centres, The Norwegian Radium Hospital – National Hospital in Oslo, and the Karolinska University Hospital in Stockholm, Sweden, and will initially establish a safe and tolerated dose of LTX-315 when given to solid tumours amenable to injection. The study received regulatory and ethical approvals at the end of last year and is currently actively including patients. Up to 40 patients with transdermally accessible solid tumours will be included. The study will investigate the primary tumour necrotic event after local injection as well as the subsequent triggering of an anti-tumour immune response such as observed in animal models. The treatment of tumours by injection of Oncopore™ as an ‘in situ vaccination’ holds the potential to become a valuable new therapy for a variety of solid tumours.

Lytix Biopharma AS intends to develop Oncopore™ to a clinical Proof-of-Concept stage whilst seeking pharma/biotech partners to support later-stage clinical development and commercialisation.
 

Gunnar Sælid, CEO
Tel +47 911 92 330

Knut Eidissen, Chairman of the Board
Tel +47 916 17 707 

In Norwegian:

Ved et møte arrangert av European Cancer Cluster (Norske Oslo Cancer Cluster og Franske Cancer-Bio-Santé Cluster) under den nylig avsluttede BIO konferansen i Boston, gav det norske legemiddelselskapet Lytix Biopharma AS en oppdatert status for fase I studien av Oncopore™ (LTX-315) i pasienter med solide svulster. Studien foregår ved Radiumhospitalet, Oslo og Karolinska Sjukhuset, Stockholm og vil inkludere opp til 40 pasienter. Studien som har mottatt tillatelse til å begynne fra legemiddelmyndigheter og etiske komiteer inkluderer nå aktivt pasienter. Primær tilbakegang av svulster vil bli undersøkt, samt at immunresponser vil bli studert slik som det har vært observert tidligere i dyr.

Lytix Biopharma AS ønsker å utvikle Oncopore™ frem til klinisk “proof-of-concept” (effektdata fra pasienter) og vil søke partnerskap med bioteknologi/farmasøytisk industri for videre produktutvikling og kommersialisering.

Gunnar Sælid, Adm. Direktør
Tel +47 911 92 330

Knut Eidissen, Styreleder
Tel +47 916 17 707